We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Immunocompromised Patients at Risk for Blastomycosis

By LabMedica International staff writers
Posted on 28 Sep 2017
Most invasive fungal infections in immunocompromised patients are caused by Zygomycetes, Aspergillus, and Candida, but literature about Blastomyces infection in immunocompromised patients has been sparse.

Blastomycosis is an infection caused by a fungus called Blastomyces. More...
The fungus lives in the environment, particularly in moist soil and in decomposing matter such as wood and leaves. People can get blastomycosis after breathing in the microscopic fungal spores from the air. Although most people who breathe in the spores do not get sick, some of those who do may have influenza-like symptoms, and the infection can sometimes become serious if it is not treated.

Scientists at Rush University Medical Center (Chicago, IL, USA) reviewed blastomycosis in cytological and surgical specimens, paying special attention to infections in immunocompromised patients. They searched their institution’s pathology files from 1994 to January 2017 for blastomycosis, and reviewed the clinical and pathologic data in detail.

The team reviewed medical history and determined immune status for each patient. Immunocompromised patients were considered to be those who had had a kidney transplant, myelodysplastic syndrome/lymphoma/leukemia, some other malignancy, diabetes mellitus, human immunodeficiency virus, viral hepatitis, sarcoidosis, end-stage renal disease, or rheumatoid arthritis. The cases in this study included 25 males and 13 females, ranging in age from 13 to 76 years. For each of the 39 cases in this study (from 38 patients), diagnosis was based on morphologic characteristics, additional studies including Periodic Acid Schiff (PAS) and Grocott Methenamine Silver (GMS) stains, and microbiology cultures when available.

The investigators reported that six of the cases in the study were cytological material, including five bronchial lavages and one brushing. A total of 32 were surgical pathology cases including 11 lung, eight soft tissue, five bone, four skin, two lymph node, one brain, and one thoracic mass. Overall, 28 patients (74%) were immunocompromised. Seven patients had disseminated infections. Thirty-four cases had one concurrent culture or more of which nine were negative.

Christine Rupcich, MD, a pathologist and lead investigator of the study, said, “Almost two-thirds of patients in our study with blastomycosis were immunocompromised. The most common location for blastomycosis infection was lung, followed by soft tissue and bone. Cultures were positive in 74% of patients with a pathology diagnosis consistent with blastomycosis.” The study was presented on September 6, 2017, at the Annual Meeting of the American Society for Clinical Pathology (ASCP) held in Chicago, IL USA.

Related Links:
Rush University Medical Center


Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.